Vir Biotechnology, Inc.

NASDAQ:VIR

Biotechnology

Healthcare
$9.15 -2.63%

-$0.25 today

Market cap
$1.57B
Beta
1.64
P/E (TTM)
-3.0
EPS (TTM)
-$3.00
52W Low $4.16High $11.66

Volume 2.15M

Average 1.76M

VIR Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Vir Biotechnology, Inc.NASDAQ: VIR

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $2.81M fell 2.0% year over year, ahead of the -10.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 3.0% from the prior quarter. Over 3 fiscal years it compounded at +19.9% a year.

Context

  • Depreciation & amortization amounted to 17.0% of revenue in FY2025, down 2.6 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -2.0% holds above the trailing-twelve-month pace of -10.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.81M-3.0% QoQ
Last fiscal yearDec 2025
$11.68M-19.8% YoY
LTMMar 2026
$11.62M-10.0% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.0%——
1 year-19.8%——
3-year CAGR+19.9%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
11.68M USD
Year-over-year change
-19.8%
4-year CAGR
+19.1%

Depreciation & Amortization vs competitors

How VIR compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -10.0% is the 7th highest of 10, against a peer median of +0.0%.
  • Depreciation & amortization amounts to 17.7% of revenue for VIR, versus a peer median of 3.9%.
VIR Competitors
Depreciation & Amortization for VIR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€676.85M EUR+122.9%+43.9%25.6%
MRNAModerna, Inc.LTM Sep 2026$257M USD+23.6%-14.8%10.2%
NVAXNovavax, Inc.LTM Mar 2026$22.34M USD-50.0%-1.7%3.7%
VIRVir Biotechnology, Inc.LTM Mar 2026$11.62M USD-10.0%+19.9%17.7%
VALNValneva SELTM Mar 2026€6.46M EUR-64.9%+1.1%4.1%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$5.95M USD+365.1%-1.1%0.6%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$4.93M USD+55.9%+19.6%7.1%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$416K USD+0.0%+17.0%—
ASMBAssembly Biosciences, Inc.LTM Mar 2026$122K USD-6.2%-36.3%0.2%
ABUSArbutus Biopharma CorporationLTM Mar 2026$44K USD-96.8%-36.6%0.0%
Peer median (excluding VIR) —+0.0%-1.1%3.9%

Competitors are the stored peer set for VIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.1B1.62B86.18M74.21M68.56M
Cost of Revenue513.87M620.97M572.83M478.65M11.71M
Gross Profit581.54M994.83M(486.65M)(404.44M)56.85M
Gross Margin53.1%61.6%-564.7%-545.0%82.9%
Research & Development448.01M474.65M579.72M506.5M432.8M
Selling, General & Admin000092.07M
Operating Expenses160.79M161.76M197.66M182.73M524.87M
Depreciation & Amortization5.81M6.78M19.45M14.56M11.68M
EBITDA555.61M761.06M(641.64M)(508.91M)(426.09M)
EBITDA Margin50.7%47.1%-744.5%-685.8%-621.5%
Operating Income420.75M833.07M(684.31M)(587.17M)(468.02M)
Operating Margin38.4%51.6%-794.0%-791.3%-682.7%
Interest Income439K28.09M86.99M71.81M40.24M
Interest Expense00000
Other Income / Expenses129.05M(78.79M)56.11M64.06M30.25M
Income Before Tax549.8M754.28M(628.19M)(523.11M)(437.77M)
Pre-Tax Margin50.2%46.7%-728.9%-704.9%-638.6%
Income Tax Expense21.22M238.44M(13.08M)(1.15M)217K
Net Income528.58M515.84M(615.06M)(521.96M)(437.99M)
Net Margin48.3%31.9%-713.7%-703.4%-638.9%
EPS (Basic)4.073.89(4.59)(3.83)(3.16)
EPS (Diluted)3.963.83(4.59)(3.83)(3.16)
Weighted Avg Shares129.88M132.61M134.13M136.25M138.52M
Weighted Avg Shares (Diluted)133.44M134.81M134.13M136.25M138.52M

Vir Biotechnology, Inc.

NASDAQ:VIR

Intrinsic Alpha fair value

Locked

Current Price

$9.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.